Ezetimibe final guidance [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-09-28 12:11 (568 d 14:18 ago) – Posting: # 20650
Views: 3,103

Hi Mutasim & all,

yesterday at BioBridges Paola Coppola (MHRA, PKWP observer) presented the state of affairs. The ezetimibe guidance is finalized and will be published soon. No changes to the draft. You are right and I was wrong. One should indeed measure both ezetimibe and its glucuronide. BE should be based on their sum* only.

I still think that’s stupid. Both methods have errors (inaccurate, imprecise). If you evaluate the sum of concentrations, errors will sum up as well. Given, the concentrations of the glucuronide are two orders of magnitude higher than the parent’s and hence, the impact of the latter is negligible.
At the BioInternational 1994 in Munich there was a nice distinction between “Need to know” and “Nice to know”. I don’t like the idea that something which is only nice to know (i.e., not used in the assessment for BE) is mandatory in a guidance. :thumb down:



Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,509 registered users;
online 15 (0 registered, 15 guests [including 6 identified bots]).
Forum time: Monday 02:29 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5